Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Sanofi is a drug manufacturers-general business based in the US. Sanofi shares (SNY) are listed on the NASDAQ and all prices are listed in US Dollars. Sanofi employs 99,412 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $51.40 |
|---|---|
| 52-week range | $43.53 - $54.26 |
| 50-day moving average | $49.84 |
| 200-day moving average | $50.86 |
| Wall St. target price | $63.63 |
| PE ratio | 18.4815 |
| Dividend yield | $3.2 (3.76%) |
| Earnings per share (TTM) | $2.77 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $51.4 from 2022-01-25
| 1 week (2022-01-19) | -1.31% |
|---|---|
| 1 month (2021-12-23) | 3.15% |
| 3 months (2021-10-26) | 2.88% |
| 6 months (2021-07-26) | -0.45% |
| 1 year (2021-01-26) | 4.58% |
|---|---|
| 2 years (2020-01-24) | 5.48% |
| 3 years (2019-01-25) | 23.05% |
| 5 years (2017-01-26) | 30.09% |
Valuing Sanofi stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sanofi's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sanofi's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Sanofi shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Sanofi's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.3485. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sanofi's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sanofi's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.3 billion.
The EBITDA is a measure of a Sanofi's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $38.5 billion |
|---|---|
| Operating margin TTM | 22.61% |
| Gross profit TTM | $25.3 billion |
| Return on assets TTM | 4.43% |
| Return on equity TTM | 9.22% |
| Profit margin | 16.04% |
| Book value | $25.24 |
| Market capitalisation | $128.9 billion |
TTM: trailing 12 months
Dividend payout ratio: 50.8% of net profits
Recently Sanofi has paid out, on average, around 50.8% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.76% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sanofi shareholders could enjoy a 3.76% return on their shares, in the form of dividend payments. In Sanofi's case, that would currently equate to about $3.2 per share.
Sanofi's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Sanofi's most recent dividend payout was on 25 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 2 May 2021 (the "ex-dividend date").
Sanofi's shares were split on a 5:1 basis on 29 September 2013. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Sanofi shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Sanofi shares which in turn could have impacted Sanofi's share price.
Over the last 12 months, Sanofi's shares have ranged in value from as little as $43.5261 up to $54.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sanofi's is 0.4819. This would suggest that Sanofi's shares are less volatile than average (for this exchange).
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
